Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17491503 | 0.83 | LMNA (0.48) | KDREGFRFGFR1RHOALMNA | |
| SCHEMBL17491488 | 0.81 | EGFR (0.42) | KDREGFRFGFR1RHOALMNA | |
| SCHEMBL17491527 | 0.79 | LMNA (0.46) | GSK3BKDREGFRFGFR1RHOA | |
| SCHEMBL17491494 | 0.79 | ALDH1A1 (0.46) | KDREGFRFGFR1RHOALMNA | |
| SCHEMBL17506981 | 0.78 | AAK1 (0.52) | GSK3BDYRK1AKDREGFRFGFR1 | |
| SCHEMBL17491395 | 0.78 | SMN1; SMN2 (0.52) | KDREGFRFGFR1RHOALMNA | |
| SCHEMBL17491394 | 0.78 | ALDH1A1 (0.49) | KDREGFRFGFR1RHOALMNA | |
| SCHEMBL17491415 | 0.77 | BRAF (0.47) | KDREGFRFGFR1RHOALMNA | |
| SCHEMBL17491452 | 0.76 | RHOA (0.39) | KDREGFRFGFR1RHOAIMPDH2 | |
| SCHEMBL17491450 | 0.76 | IMPDH2 (0.46) | DYRK1AKDREGFRFGFR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982670-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-2982670-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | GSK3B 2149/4885DYRK1A 4878/4885KDR 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.